Aisling Capital believes the next decade will be marked by a revolution in healthcare driven by new therapeutics generated by biotechnology. The completion of the human genome has given scientists new insights into the causes of human disease. These insights, combined with the past 20 years of developments in the biotechnology industry, are leading to rapid expansion of novel approaches toward the diagnosis, prevention, and treatment of life-threatening illnesses. These advances have led to an ever-increasing demand for capital to complete the development and commercialization of new therapeutics. Our goal is to support the leading global healthcare companies that are building on these technical and medical breakthroughs to commercialize new healthcare products.
View Top Employees from Aisling CapitalWebsite | http://www.aislingcapital.com/ |
Revenue | $5.6 million |
Employees | 20 (17 on RocketReach) |
Founded | 2000 |
Address | 888 7th Avenue 12th Floor, New York, New York 10106, US |
Phone | (212) 651-6380 |
Fax | (212) 651-6379 |
Industry | Venture Capital and Private Equity Principals, Finance General, Finance |
Competitors | 5AM Ventures, Linden Capital Partners, MPM, RA Capital Management, L.P., Telegraph Hill Partners |
SIC | SIC Code 628 Companies, SIC Code 62 Companies |
NAICS | NAICS Code 523 Companies, NAICS Code 52 Companies, NAICS Code 5239 Companies, NAICS Code 52393 Companies |
Looking for a particular Aisling Capital employee's phone or email?
The Aisling Capital annual revenue was $5.6 million in 2024.
17 people are employed at Aisling Capital.
Aisling Capital is based in New York, New York.
The NAICS codes for Aisling Capital are [523, 52, 5239, 52393].
The SIC codes for Aisling Capital are [628, 62].